European League Against Rheumatism (EULAR) (04/01/2015) Skingle, Diana

Biosimilar medicines could help lower the cost of original biologics, and the European League Against Rheumatism (EULAR) Standing Committee of People with Arthritis/Rheumatism in Europe (SCPARE) welcomes the possibility of increased treatment choice and more effective disease management. As with all new medicines, however, biosimilars have raised questions and concerns about issues such as the approval process, who regulates biosimilars, and the drugs' safety and risk. Patients and patient organizations require reliable, up-to-date, evidence-based information to aid their understanding of biosimilars and help them make informed decisions. Because the science of biosimilars is not easy for the average person to understand, there are many questions and persistent anxiety and skepticism about biosimilars. EULAR SCPARE is calling on the scientific community to make available to patients timely lay summaries of the results of relevant and important studies and reviews involving biosimilars. The increase of available data on biosimilars also should lead to reliable codes of practice, recommendations, and points to consider developed by EULAR.

Web Link 

Abstract News © 2015 INFORMATION, INC.

Access other Therapeutic Areas:


 

New & Noteworthy